Article Text

This article has a correction. Please see:

Download PDFPDF
Are laboratory tests useful for monitoring the activity of lupus nephritis? A 6-year prospective study in a cohort of 228 patients with lupus nephritis
  1. G Moroni1,
  2. A Radice4,
  3. G Giammarresi2,
  4. S Quaglini3,
  5. B Gallelli1,
  6. A Leoni1,
  7. M L Vecchi2,
  8. P Messa1,
  9. R A Sinico4
  1. 1
    Division of Nephrology, Fondazione Ospedale Maggiore, Mangiagalli, Regina Elena, Milan, Italy
  2. 2
    Chair of Nephrology, University of Palermo, Palermo, Italy
  3. 3
    Dipartimento di Informatica e Sistemistica, Universita’ degli Studi di Pavia
  4. 4
    Renal Unit and Clinical Immunology Unit, Azienda Ospedaliera, Ospedale San Carlo Borromeo, Milan, Italy
  1. Gabriella Moroni, Divisione di Nefrologia e Dialisi, Fondazione Ospedale Maggiore IRCCS, Via della Commenda 15–20122 Milano (Italy); gmoroni{at}policlinico.mi.it

Abstract

Objectives: To evaluate the role of immunological tests for monitoring lupus nephritis (LN) activity.

Methods: C3, C4, anti-dsDNA and anti-C1q antibodies were prospectively performed over 6 years in 228 patients with LN.

Results: In membranous LN only anti-C1q antibodies differentiated proteinuric flares from quiescent disease (p = 0.02). However, in this group 46% of flares occurred with a normal value of anti-C1q antibodies versus 20% in proliferative LN (p = 0.02). In patients with antiphospholipid antibodies (APL), 33% of flares occurred with normal levels of anti-C1q antibodies versus 14.5% in patients that were APL-negative (p = 0.02). In proliferative LN, anti-C1q antibodies showed a slightly better sensitivity and specificity (80.5 and 71% respectively) than other tests for the diagnosis of renal flares. All four tests had good negative predictive value (NPV). At univariate analysis anti-C1q was the best renal flare predictor (p<0.0005). At multivariate analysis, the association of anti-C1q with C3 and C4 provided the best performance (p<0.0005, p<0.005, p<0.005 respectively).

Conclusions: Anti-C1q is slightly better than the other tests to confirm the clinical activity of LN, particularly in patients with proliferative LN and in the absence of APL. All four “specific” tests had a good NPV, suggesting that, in the presence of normal values of each, active LN is unlikely.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Competing interests: None.

  • Present address for AR: Institute of Microbiology, Azienda Ospedaliera, Ospedale San Carlo Borromeo, Milan, Italy.

Linked Articles

  • Correction
    BMJ Publishing Group Ltd and European League Against Rheumatism